This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Ethics Remove Pharmacology Remove Safety Related Topics
Medical science Prospecting Healthcare Provider Prescription Healthcare Pharma Competition Patients FDA Leads More Related Topics >
article thumbnail

Legal challenges put off label use of gender affirming care drugs in jeopardy

Pharmaceutical Technology

MARCH 16, 2023

However, health specialists refute most safety concerns for the use of drug classes as part of gender affirming care, citing years of research and care. As these drugs are not licensed for the specific indication of gender-affirming care, collecting safety data on off-label use is not viewed as a priority.

Ethics 144
Ethics Prescription Safety Healthcare 144
article thumbnail

Why R&D innovation holds the key to greater patient impact

European Pharmaceutical Review

MAY 2, 2023

By collaborating with several stakeholders and authorities, multiple stages of development can take place concurrently to speed up R&D without compromising safety protocols. The COVID-19 blueprint has shown a way forward. Previously, he spent more than 10 years at Roche in multiple positions within medical affairs.

Patients 99
Patients Medicine Marketing Medical 99
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 8,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024